Immatics and Bristol Myers Squibb Expand Alliance to Develop Cell Therapy Programmes
By Swati Sharan
Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)
Published: 22 Jun-2022
DOI: 10.3833/pdr.v2022.i6.2698 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Immatics and Bristol Myers Squibb (BMS) have expanded their strategic partnership to develop multiple allogeneic TCR-T and/or CAR-T programmes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS